Aarti Pharmalabs Q1 FY27: Xanthine momentum, capacity ramp-up, and a CDMO build-out

Aarti Pharmalabs Limited reported a strong start to FY27, with Q1 standalone operational revenue of INR 5,346 million (INR 534.6 crore), up 42.4% year on year. EBITDA was INR 1,327 million (INR 132.7 crore), up 39.5% year on year, while PAT came in at INR 713 million (INR 71.3 crore), up 49.2% year on year. EBITDA margin was 24.82% and PAT margin was 13.34% for the quarter.

The quarter was defined by two forces playing out at the same time. First, the xanthine derivatives business delivered the highest-ever quarterly sales, benefiting from a combination of volume growth and elevated realizations linked to raw material movements. Second, the API business saw a temporary production impact due to a planned shutdown for debottlenecking in the steroid API block. In parallel, management reiterated that CDMO and CMO revenues tend to be second-half heavy, even as the company continues to add project depth and invest behind dedicated capacity.

What drove the quarter: segment mix and xanthine strength

The company operates three core verticals: xanthine derivatives, API and intermediates, and CDMO and CMO services. In Q1 FY27, xanthine derivatives accounted for 57% of standalone revenue, APIs and intermediates contributed 30%, CDMO and CMO contributed 7%, and the remaining 6% was categorized as others.

Within xanthine, management highlighted a clear skew towards beverages. The Q1 sales quantity split was 74% beverages and 26% others. The business was also export-led, with the Q1 geographical split at 79% international and 21% domestic. Management indicated that as new capacity ramps up, export contribution is expected to remain structurally higher than domestic.

A key management takeaway was the way realizations move in xanthine. The company emphasized that raw material pass-through is common in customer contracts, which means EBITDA percentage can get distorted during periods of sharp input inflation. Management noted that realizations per kg are expected to decline as supply chains ease, but positioned the volume ramp-up from the expanded capacity as the offset.

Capacity additions: xanthine ramp, Atali commissioning, and a dedicated CDMO block

Aarti Pharmalabs has been investing behind capacity for both xanthine and CDMO. On the xanthine side, the investor presentation states that two dedicated plants at Tarapur have a combined capacity of 9,600+ MTPA. Capacity has expanded from 5,000 MTPA to 9,600+ MTPA, with phased ramp-up underway till FY27 end. Management also stated an intent to increase global market share from 15 to 20% towards 20 to 25% over the next two years.

On the CDMO side, Atali is central to the scale-up. Management stated that both phases of Atali Block 1 with 440 kL reactor capacity will become fully operational in Q2 FY27. Beyond Block 1, the company has announced Atali Block 2, a brownfield capex project designed to support specific CDMO and CMO projects.

The Atali Block 2 project, as per the investor presentation, involves an estimated investment of INR 149 crores with an estimated capacity of about 405 kL. Commercialization is guided for H2 FY28, and management stated that groundbreaking is planned in Q3 FY27. The strategic rationale highlighted in the presentation is that the block is intended to be dedicated for certain CDMO and CMO projects to ensure supply continuity and deliver better payback via a more cost-effective design.

Separately, management also stated that the company is initiating R&D investment in FY27 towards TIDES, specifically peptides and oligonucleotides, to expand portfolio capabilities.

Operating updates: debottlenecking, pricing pressure in APIs, and CDMO seasonality

The investor presentation and concall both note that production at the Unit 4 steroid API block was temporarily impacted by a 6-week debottlenecking shutdown. Management stated that the exercise successfully unlocked a one-third capacity increase. The company expects normalization as the shutdown is behind it and indicated that the enhanced capacity should see higher utilization going forward.

In APIs and intermediates, management acknowledged that pricing pressures in existing molecules remain. The company stated it is working on development of new molecules with medium-term patent expiries and is also starting a special project aimed at process intensification and cost reduction in existing products to mitigate the headwinds.

In CDMO and CMO, the company disclosed that it is working with 22 customers and has 57 active projects, including 37 commercial projects and 20 under development. Management reiterated that CDMO revenues are likely to remain skewed towards the second half of the year and maintained its guidance of 40 to 50% growth for FY27.

Financial summary

Note: The financial tables include a note that fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability, with previous quarterly figures restated accordingly.

Guidance and what to watch

Management outlined a medium-term ambition of 15 to 18% revenue and EBITDA CAGR over the next 3 to 4 years. For FY27, the company indicated that capex is expected at levels similar to FY26, when capex reached about INR 400 crore.

For margins, management indicated a standalone EBITDA margin guidance of 22% to 25% for the full year, with outcomes dependent on how quickly expanded capacities are operationalized and ramped. In xanthine, management avoided guiding a segment-level EBITDA percentage due to pass-through dynamics, but emphasized sustaining absolute gross profit through higher volumes.

Two disclosure points matter for interpretation. First, consolidated financials include a note that the Ganesh Polychem relationship became a joint venture with effect from April 1, 2025, and the consolidated accounts are prepared using the equity method, making current period numbers not comparable with previous periods. Second, the company’s reported profitability can be influenced by fair value movement on long-dated USD forwards.

Closing view

Q1 FY27 reflected strong year-on-year growth led by xanthine derivatives, while the API business absorbed a temporary impact from planned debottlenecking that management expects to translate into higher steroid capacity going forward. The strategic narrative remains centered on three parallel tracks: ramping xanthine capacity, strengthening regulated API capabilities through capacity unlocks, and scaling CDMO through Atali commissioning and a dedicated Block 2 capex.

The next few quarters will likely be judged on two operational outcomes: how smoothly the xanthine ramp progresses as realizations normalize, and whether CDMO revenues materialize in line with the second-half seasonality and the 40 to 50% growth guidance. The Atali investment cycle and the early steps into TIDES R&D will also be important markers of the company’s longer-term capability expansion.